270 related articles for article (PubMed ID: 16138249)
41. Aspartoacylase catalytic deficiency as the cause of Canavan disease: a structural perspective.
Wijayasinghe YS; Pavlovsky AG; Viola RE
Biochemistry; 2014 Aug; 53(30):4970-8. PubMed ID: 25003821
[TBL] [Abstract][Full Text] [Related]
42. A case of juvenile Canavan disease with distinct pons involvement.
Çakar NE; Aksu Uzunhan T
Brain Dev; 2020 Feb; 42(2):222-225. PubMed ID: 31839386
[TBL] [Abstract][Full Text] [Related]
43. Canavan disease and the role of N-acetylaspartate in myelin synthesis.
Namboodiri AM; Peethambaran A; Mathew R; Sambhu PA; Hershfield J; Moffett JR; Madhavarao CN
Mol Cell Endocrinol; 2006 Jun; 252(1-2):216-23. PubMed ID: 16647192
[TBL] [Abstract][Full Text] [Related]
44. Alport syndrome. Molecular genetic aspects.
Hertz JM
Dan Med Bull; 2009 Aug; 56(3):105-52. PubMed ID: 19728970
[TBL] [Abstract][Full Text] [Related]
45. Canavan disease: studies on the knockout mouse.
Matalon R; Michals-Matalon K; Surendran S; Tyring SK
Adv Exp Med Biol; 2006; 576():77-93; discussion 361-3. PubMed ID: 16802706
[TBL] [Abstract][Full Text] [Related]
46. [Galactosemia: the genotype and phenotype of seven patients].
Martins E; Teixeira J; Cardoso ML; Lima MR; Briones-Godino P; Barbot C
Rev Neurol; 2004 Jun 16-30; 38(12):1132-5. PubMed ID: 15229825
[TBL] [Abstract][Full Text] [Related]
47. Spongy degeneration of the brain, Canavan disease: biochemical and molecular findings.
Matalon RM; Michals-Matalon K
Front Biosci; 2000 Mar; 5():D307-11. PubMed ID: 10704428
[TBL] [Abstract][Full Text] [Related]
48. Uncoupling N-acetylaspartate from brain pathology: implications for Canavan disease gene therapy.
von Jonquieres G; Spencer ZHT; Rowlands BD; Klugmann CB; Bongers A; Harasta AE; Parley KE; Cederholm J; Teahan O; Pickford R; Delerue F; Ittner LM; Fröhlich D; McLean CA; Don AS; Schneider M; Housley GD; Rae CD; Klugmann M
Acta Neuropathol; 2018 Jan; 135(1):95-113. PubMed ID: 29116375
[TBL] [Abstract][Full Text] [Related]
49. Aspartoacylase deficiency and N-acetylaspartic aciduria in patients with Canavan disease.
Matalon R; Michals K; Sebesta D; Deanching M; Gashkoff P; Casanova J
Am J Med Genet; 1988 Feb; 29(2):463-71. PubMed ID: 3354621
[TBL] [Abstract][Full Text] [Related]
50. Mild elevation of N-acetylaspartic acid and macrocephaly: diagnostic problem.
Surendran S; Bamforth FJ; Chan A; Tyring SK; Goodman SI; Matalon R
J Child Neurol; 2003 Nov; 18(11):809-12. PubMed ID: 14696913
[TBL] [Abstract][Full Text] [Related]
51. Nur7 is a nonsense mutation in the mouse aspartoacylase gene that causes spongy degeneration of the CNS.
Traka M; Wollmann RL; Cerda SR; Dugas J; Barres BA; Popko B
J Neurosci; 2008 Nov; 28(45):11537-49. PubMed ID: 18987190
[TBL] [Abstract][Full Text] [Related]
52. Global CNS gene transfer for a childhood neurogenetic enzyme deficiency: Canavan disease.
Leone P; Janson CG; McPhee SJ; During MJ
Curr Opin Mol Ther; 1999 Aug; 1(4):487-92. PubMed ID: 11713764
[TBL] [Abstract][Full Text] [Related]
53. A new T677C mutation of the aspartoacylase gene encodes for a protein with no enzymatic activity.
Di Pietro V; Gambacurta A; Amorini AM; Finocchiaro A; D'Urso S; Ceccarelli L; Tavazzi B; Giardina B; Lazzarino G
Clin Biochem; 2008 May; 41(7-8):611-5. PubMed ID: 18280251
[TBL] [Abstract][Full Text] [Related]
54. Identification of the zinc binding ligands and the catalytic residue in human aspartoacylase, an enzyme involved in Canavan disease.
Herga S; Berrin JG; Perrier J; Puigserver A; Giardina T
FEBS Lett; 2006 Oct; 580(25):5899-904. PubMed ID: 17027983
[TBL] [Abstract][Full Text] [Related]
55. Clinically Distinct Phenotypes of Canavan Disease Correlate with Residual Aspartoacylase Enzyme Activity.
Mendes MI; Smith DE; Pop A; Lennertz P; Fernandez Ojeda MR; Kanhai WA; van Dooren SJ; Anikster Y; Barić I; Boelen C; Campistol J; de Boer L; Kariminejad A; Kayserili H; Roubertie A; Verbruggen KT; Vianey-Saban C; Williams M; Salomons GS
Hum Mutat; 2017 May; 38(5):524-531. PubMed ID: 28101991
[TBL] [Abstract][Full Text] [Related]
56. Canavan disease: diagnosis and molecular analysis.
Matalon R
Genet Test; 1997; 1(1):21-5. PubMed ID: 10464621
[TBL] [Abstract][Full Text] [Related]
57. Reliable prenatal diagnosis of Canavan disease by measuring N-acetylaspartate in amniotic fluid using liquid chromatography tandem mass spectrometry.
Al-Dirbashi OY; Kurdi W; Imtiaz F; Ahmad AM; Al-Sayed M; Tulbah M; Al-Nemer M; Rashed MS
Prenat Diagn; 2009 May; 29(5):477-80. PubMed ID: 19235826
[TBL] [Abstract][Full Text] [Related]
58. N-Acetylaspartate Synthase Deficiency Corrects the Myelin Phenotype in a Canavan Disease Mouse Model But Does Not Affect Survival Time.
Maier H; Wang-Eckhardt L; Hartmann D; Gieselmann V; Eckhardt M
J Neurosci; 2015 Oct; 35(43):14501-16. PubMed ID: 26511242
[TBL] [Abstract][Full Text] [Related]
59. Spectrum of mutations in MMACHC, allelic expression, and evidence for genotype-phenotype correlations.
Lerner-Ellis JP; Anastasio N; Liu J; Coelho D; Suormala T; Stucki M; Loewy AD; Gurd S; Grundberg E; Morel CF; Watkins D; Baumgartner MR; Pastinen T; Rosenblatt DS; Fowler B
Hum Mutat; 2009 Jul; 30(7):1072-81. PubMed ID: 19370762
[TBL] [Abstract][Full Text] [Related]
60. Mutation analysis of PEX7 in 60 probands with rhizomelic chondrodysplasia punctata and functional correlations of genotype with phenotype.
Braverman N; Chen L; Lin P; Obie C; Steel G; Douglas P; Chakraborty PK; Clarke JT; Boneh A; Moser A; Moser H; Valle D
Hum Mutat; 2002 Oct; 20(4):284-97. PubMed ID: 12325024
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
